Nanjing Fangshenghe Pharmaceutical Technology

Nanjing Fangshenghe Pharmaceutical Technology is a China-based pharmaceutical company specializing in the research, development, and commercialization of high-end generic and innovative small molecule drugs. Founded in 2014 and headquartered in Nanjing, the company focuses on therapeutic areas including cardiovascular disease, metabolic disorders, and the central nervous system. Fangshenghe is particularly recognized for its expertise in complex formulation and crystal form research, having successfully developed generic versions of blockbuster drugs such as Sacubitril/Valsartan. The company maintains a robust pipeline of both improved generics and novel chemical entities aimed at addressing significant unmet medical needs in the Chinese and global markets.